Pediatric HCT in Florida (2014 -2016): A report from the FPBCC.
Florida consortium
outcomes
pediatric HCT
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
17
09
2020
received:
30
05
2020
accepted:
03
11
2020
pubmed:
28
11
2020
medline:
29
1
2022
entrez:
27
11
2020
Statut:
ppublish
Résumé
FPBCC was formed in 2018 by five pediatric transplant programs in Florida. One of the key objectives of the consortium is to provide outcome analyses by combining HCT data from all the participating centers in order to identify areas for improvement. In this first FPBCC landscape report we describe the patient and transplant characteristics of pediatric patients undergoing first allo and auto HCT between 2014 and 2016 in Florida. The source of data was eDBtC of the CIBMTR. Over the span of 3 years, a total of 230 pediatric patients underwent allo-HCT and 104 underwent auto-HCT at the participating centers. The most significant predictor of survival in allo-HCT recipients with malignant disorders was the degree of HLA- match, while in the recipients of allo-HCT with non-malignant disorders the predictors of survival included age, donor relationship and degree of HLA match. Our analyses identified the need to improve reporting of primary cause of death and improve on donor selection process given that the degree of HLA match remains the most important predictor of survival. This first FPBCC-wide review describes the trends in pediatric HCT activity between 2014 and 2016 among the participating centers in Florida and confirms feasibility of using eDBtC data platform and collaborative approach in order to identify areas for improvement in outcomes.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13931Subventions
Organisme : Public Health Service grant/cooperative agreement
ID : U24CA076518
Organisme : the National Heart, Lung and Blood Institute
ID : U24HL138660
Organisme : the National Heart, Lung and Blood Institute
ID : R21HL140314
Organisme : the National Heart, Lung and Blood Institute
ID : U01HL128568
Organisme : the National Heart, Lung and Blood Institute
ID : R01HL131731
Organisme : the National Heart, Lung and Blood Institute
ID : R01HL126589
Organisme : the National Institute of Allergy and Infectious Diseases
Organisme : HRSA HHS
ID : HHSH250201700006C
Pays : United States
Organisme : HRSA HHS
ID : SC1MC31881-01-00
Pays : United States
Organisme : Naval Research
ID : N00014-18-1-2888
Organisme : Naval Research
ID : N00014-17-1-2850
Organisme : NIH HHS
ID : 5P01CA111412
Pays : United States
Organisme : NIH HHS
ID : 5R01HL129472
Pays : United States
Organisme : NIH HHS
ID : R01CA152108
Pays : United States
Organisme : NIH HHS
ID : 1R01HL131731
Pays : United States
Organisme : NIH HHS
ID : 1U01AI126612
Pays : United States
Organisme : NIH HHS
ID : 1R01CA231141
Pays : United States
Organisme : the National Cancer Institute
ID : U24HL138660
Organisme : the National Cancer Institute
ID : R21HL140314
Organisme : the National Cancer Institute
ID : U01HL128568
Organisme : the National Cancer Institute
ID : R01HL131731
Organisme : the National Cancer Institute
ID : R01HL126589
Organisme : HRSA HHS
ID : HHSH250201700006C
Pays : United States
Organisme : HRSA HHS
ID : SC1MC31881-01-00
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010;45(2):219-234.
Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357(15):1472-1475.
Khera N, Gooley T, Flowers MED, et al. Association of distance from transplantation center and place of residence on outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(7):1319-1323.
Schriber JR, Hari PN, Ahn KW, et al. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report. Cancer. 2017;123(16):3141-3149.
Loberiza FR Jr, Serna DS, Horowitz MM, Rizzo JD. Transplant center characteristics and clinical outcomes after hematopoietic stem cell transplantation: what do we know? Bone Marrow Transplant. 2003;31(6):417-421.
Khandelwal P, Millard HR, Thiel E, et al. Hematopoietic stem cell transplantation activity in pediatric cancer between 2008 and 2014 in the United States: a center for international blood and marrow transplant research report. Biol Blood Marrow Transplant. 2017;23(8):1342-1349.
Brissot E, Labopin M, Ehninger G, et al. Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the acute leukemia working party of the EBMT. Haematologica. 2019;104(3):524-532.
Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31(10):1310-1316.
Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033-1040.
Dehn J, Spellman S, Hurley CK, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019;134(12):924-934.